Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | SMARCA2 | P51531 | 2/20 | 0.51 |
| ▸ | MITF | O75030 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | ACP1 | P24666 | 1/20 | 0.51 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.50 |
| ▸ | APAF1 | O14727 | 1/20 | 0.49 |
| ▸ | NSD2 | O96028 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | TOP2A | P11388 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29504400 | 1.00 | KMT2A (0.51) | KMT2AMEN1LMNAKDM4ESMARCA2 | |
| SCHEMBL7973929 | 0.91 | POLB (0.54) | KMT2ALMNAKDM4EPOLBGAA | |
| SCHEMBL11722763 | 0.85 | DRD3 (0.59) | KMT2AMEN1SMARCA2L3MBTL1GAA | |
| SCHEMBL5884397 | 0.84 | DRD3 (0.57) | KMT2AMEN1SMARCA2POLBL3MBTL1 | |
| SCHEMBL3879184 | 0.83 | KAT2B (0.47) | KMT2AMEN1LMNAKDM4EPOLB | |
| SCHEMBL6528467 | 0.82 | L3MBTL1 (0.53) | KMT2AMEN1LMNAKDM4ESMARCA2 | |
| SCHEMBL10129706 | 0.82 | KMT2A (0.53) | KMT2AMEN1LMNAKDM4ESMARCA2 | |
| Hydrochloric Acid SCHEMBL3882917 | 0.81 | KAT2B (0.46) | KMT2AMEN1KDM4EPOLBL3MBTL1 | |
| SCHEMBL13500541 | 0.81 | KDM4E (0.55) | KMT2AMEN1LMNAKDM4ESMARCA2 | |
| SCHEMBL15956750 | 0.81 | KMT2A (0.53) | KMT2AMEN1LMNAKDM4ESMARCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220380341-A1 | INHIBITORS OF HIV-1 NEF FOR THE TREATMENT OF HIV DISEASE | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-12-01 | — | — | US | disclosed |
| WO-2020240492-A1 | 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2020-12-03 | — | — | WO | disclosed |
| WO-2020081856-A1 | INHIBITORS OF HIV-1 NEF FOR THE TREATMENT OF HIV DISEASE | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2020-04-23 | — | — | WO | disclosed |
| WO-2012007006-A1 | TRIAZOLO- AND PYRAZOLOQUINAZOLINE DERIVATIVES AS PDE10A ENZYME INHIBITOR | H. LUNDBECK A/S (DK) | 2012-01-19 | — | — | WO | disclosed |
| US-7635774-B2 | 2-Amino-imidazole derivatives; modulate the expression and/or function of proteins involved in inflammation, immune response regulation and cell proliferation | AMGEN INC. (US) | 2009-12-22 | — | — | US | disclosed |
| WO-2005021547-A2 | HETEROCYCLIC CANNABINOID CB2 RECEPTOR ANTAGONISTS | PHARMAXIS PTY LTD. (AU) | 2005-03-10 | — | — | WO | disclosed |
| US-4053472-A | MICROBIOCIDES | SCHERING AKTIENGESELLSCHAFT (DT) | 1977-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220380341-A1 | INHIBITORS OF HIV-1 NEF FOR THE TREATMENT OF HIV DISEASE | NAT1, CXCR4, HAX1 | KMT2A 3244/4885MEN1 4741/4885LMNA 3289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.